Quitting EU regulator 'would leave UK waiting longer' for new drugs

Drug firms say leaving EMA could mean Britons having to wait a year longer than EU citizens for newly-developed medicines

Ministers are coming under growing pressure to scrap plans to quit Europe's medicines regulator as part of Brexit, with drug firms saying doing so could force Britons to wait a year longer than patients in the EU to access new drugs.

Labour and leaders of the UK's pharmaceutical industry fear that patients and the NHS will lose out if Britain gives up its membership of the European Medicines Agency (EMA). The health secretary, Jeremy Hunt, told MPs last week that he did not expect the UK to continue as a member once it left the EU.